Egypt removed obstacles to making pharmaceutical treatments available to patients: Novartis country president

Doaa A.Moneim , Tuesday 1 Nov 2022

Over the past few years, Egypt has removed obstacles to making vital pharmaceutical treatments available to patients through the mechanisms of the Unified Purchasing Authority and the Egyptian Drug Authority, said Sherif Amin, the country president at Novartis Egypt.



Amin made his comments during the third edition of Al-Ahram Establishment’s pharmaceutical conference that concluded on Monday.

He also asserted the importance of the presidential initiatives that Egypt has launched over the past few years that help patients access the best available treatments.

“The Egyptian Drug Authority tracks the global pharmaceutical market to identify the new drugs to avail them in the local market. The government counts heavily on the drugs authority and other entities in the health sector in the country for the sake of improving the healthcare services. Novartis serves over 10 million citizen in the country through availing innovative treatments. Our factory in Egypt produces more than 75 million drug packs, 21 million of which are exported globally,” Amin explained.

Amin added that meeting Egypt Vision 2030’s healthcare-related goals requires continuing dialogue among actors in the healthcare sector in order to remove the obstacles they face at all stages, from drugs manufacturing down to making them available in the local market.

He also urged the concerned bodies to focus on supervising the local market in a way that contributes to serving patients without negatively affecting the quality of their treatment.

In this respect, Amin pointed to the actions Novartis has taken to provide treatments in the Egyptian market in collaboration with the drugs authorities, which had a significant impact, especially amid the cascading global challenges.

Short link: